naftidrofuryl.txt

oxalate

CLINICAL USE

Vasodilator:Peripheral and cerebral vascular disease

DOSE IN NORMAL RENAL FUNCTION

Peripheral vascular disease: 100–200 mg 3 times dailyCerebral vascular disease: 100 mg 3 times daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :473.6

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60–65

%Excreted unchanged in urine &nbsp &nbsp : <1 (mainly as metabolites)

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :61.5 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1–2/3.5

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Dialysed. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

IV preparation was withdrawn due to increased risk of cardiac and neurological toxicity. It has also been associated with acute renal failure secondary to oxalate crystallisationnaftidrofuryl oxalate.

Tags: post-by-auto-php